Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Cates, CJ"'
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease. Combining these treatments, which have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::87b8e3045f5ff0f8f90e083b81bf8974
https://openaccess.sgul.ac.uk/id/eprint/2674/1/CD008989.pdf
https://openaccess.sgul.ac.uk/id/eprint/2674/1/CD008989.pdf
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be conside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::0974e86ccdf01cf957aa6290b438692d
https://openaccess.sgul.ac.uk/id/eprint/2678/1/CD003137.pdf
https://openaccess.sgul.ac.uk/id/eprint/2678/1/CD003137.pdf
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropiumare commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::095a1eaec676e5f002d5f2e48b41d439
https://openaccess.sgul.ac.uk/id/eprint/2682/1/CD009039.pdf
https://openaccess.sgul.ac.uk/id/eprint/2682/1/CD009039.pdf
Publikováno v:
Cochrane Database Syst Rev
Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler. However, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::71130ef66bf0e1d2671983e29d04101f
https://openaccess.sgul.ac.uk/id/eprint/2680/1/CD007033.pdf
https://openaccess.sgul.ac.uk/id/eprint/2680/1/CD007033.pdf
Autor:
Cates, CJ, Lasserson, TJ
Background\ud Formoterol has a fast onset of action and can therefore be used to relieve symptoms of asthma. A combination inhaler can deliver formoterol with different doses of inhaled corticosteroid; when used as a reliever both drugs will be deliv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6f3edb9583b00a3cbb607c6975f181f2
https://openaccess.sgul.ac.uk/id/eprint/2693/1/CD007085.pdf
https://openaccess.sgul.ac.uk/id/eprint/2693/1/CD007085.pdf
Autor:
Cates, CJ, Lasserson, TJ
Background\ud Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy. The combination of formoterol and budesonide in a single inhaler introduces the possibility of using a single inhaler for both prevention
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::cceacd1790e9f029fd4954684ca18cc6
https://openaccess.sgul.ac.uk/id/eprint/2692/1/CD007313.pdf
https://openaccess.sgul.ac.uk/id/eprint/2692/1/CD007313.pdf
Background\ud Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::39de2390a72d037d70d3b2834f54b9ea
https://openaccess.sgul.ac.uk/id/eprint/2695/1/CD006924.pdf
https://openaccess.sgul.ac.uk/id/eprint/2695/1/CD006924.pdf
Background\ud People with asthma who come from minority groups have poorer asthma outcomes and more asthma related visits to Emergency Departments (ED). Various programmes are used to educate and empower people with asthma and these have previously b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::96d37f20d63cfc314a615b07465521ce
https://openaccess.sgul.ac.uk/id/eprint/2694/1/CD006580.pdf
https://openaccess.sgul.ac.uk/id/eprint/2694/1/CD006580.pdf
Epidemiological evidence has suggested a link between beta(2)-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe.Obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::7299b52b3aaf4a7571969b0e4e4fbc37
https://openaccess.sgul.ac.uk/id/eprint/2696/1/CD006922.pdf
https://openaccess.sgul.ac.uk/id/eprint/2696/1/CD006922.pdf